Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;26(3):293.
doi: 10.3892/mmr.2022.12810. Epub 2022 Aug 3.

Novel splice‑site variants c.393G>A, c.278_2A>G in exon 2 and Q705K variant in exon 3 of NLRP3 gene are associated with bipolar I disorder

Affiliations

Novel splice‑site variants c.393G>A, c.278_2A>G in exon 2 and Q705K variant in exon 3 of NLRP3 gene are associated with bipolar I disorder

Kuyaş Heki̇mler Öztürk et al. Mol Med Rep. 2022 Sep.

Abstract

NOD‑like receptor pyrin domain‑containing 3 (NLRP3) has been considered to play a crucial role in triggering the host's immune and inflammatory responses. Genetic variants are critical determinants of interindividual variances in inflammatory responses and clinical outcomes. The role of NLRP3 gene variations in bipolar I (BPI) disorder, which is known to include genetic factors in its aetiology, has not been previously reported, at least to the best of our knowledge. The present study aimed to determine the role and frequency ofta exon 2 and exon 3 variants of NLRP3 in BPI disorder and to evaluate the association between different phenotypic traits. A case‑control study with 123 patients and 107 healthy controls was conducted to investigate the association of variants identified in the exon 2 and exon 3 regions of NLRP3, with the risk of BPI. Regions of interest were sequenced using a PCR‑based Sanger sequencing method. Three BPI‑related variants were identified. The genotype Q705K CA was detected more frequently in BPI patients, as compared to the control group [P<0.001; odds ratio (OR), 0.202; 95% confidence interval (CI), 0.080‑0.508]. In addition, two novel splice‑site variants (c.393G>A and c.278_2A>G) that, to the best of our knowledge, have not been previously reported in any database, were detected only in the BPI patient group [P<0.001; OR, 0.846; 95% CI, 0.784‑0.912; P<0.001; OR, 0.886; 95% CI, 0.832‑0.944, respectively]. There was no significant association between the Q795K variant and phenotypic traits (P>0.05). However, there was a significant association between those carrying the heterozygous c.393G>A variant and a positive family history (P=0.043). It was also observed that those with the heterozygous c.278‑2A>G variant presented with a significantly early‑onset (P=0.003). On the whole, the data of the present study suggested that NLRP3 plays a crucial role in the pathogenesis of BPI and may be a potential risk factor. However, further functional studies and repeated studies in other populations are required to properly comprehend the roles of the NLRP3 variants in the risk of developing BPI.

Keywords: NOD‑like receptor pyrin domain‑­containing 3; bipolar disorder; neuroinflammation; polymorphism; splice‑site variant.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1.
Figure 1.
Schematic structure of the NLRP3 gene and Sanger chromatogram image of the detected variants. (A) Wild-type and heterozygous Sanger chromatogram image of novel splice-site c.278_2A>G variant, detected in the exon 2 of the NLRP3 gene. (B) Wild-type and heterozygous Sanger chromatogram image of novel splice-site c.393G>A variant, detected in the exon 2 of the NLRP3 gene. (C) Wild-type and heterozygous Sanger chromatogram image of the Q705K variant detected in the exon 3 of the NLRP3 gene. (D) Schematic representation of NLRP3 gene structure and identified variants in patients with BPI. NOD-like receptor pyrin domain-containing 3; BPI, bipolar I disorder.

Similar articles

Cited by

References

    1. Pereira AC, Oliveira J, Silva S, Madeira N, Pereira CM, Cruz MT. Inflammation in bipolar disorder (BD): Identification of new therapeutic targets. Pharmacol Res. 2021;163:105325. doi: 10.1016/j.phrs.2020.105325. - DOI - PubMed
    1. Gubert C, Andrejew R, Moritz CE, Dietrich F, Vasconcelos-Moreno MP, Dos Santos BT, Fijtman A, Kauer-Sant'Anna M, Kapczinski F, da Silva Magalhães PV, Battastini AM. Bipolar disorder and 1513A>C P2RX7 polymorphism frequency. Neurosci Lett. 2019;16:143–147. doi: 10.1016/j.neulet.2018.11.055. - DOI - PubMed
    1. Prata DP, Costa-Neves B, Cosme G, Vassos E. Unravelling the genetic basis of schizophrenia and bipolar disorder with GWAS: A systematic review. J Psychiatr Res. 2019;114:178–207. doi: 10.1016/j.jpsychires.2019.04.007. - DOI - PubMed
    1. Gordovez FJ, McMahon FJ. The genetics of bipolar disorder. Mol Psychiatry. 2020;25:544–559. doi: 10.1038/s41380-019-0634-7. - DOI - PubMed
    1. Gunderson JG, Zanarini MC, Choi-Kain LW, Mitchell KS, Jang KL, Hudson JI. Family study of borderline personality disorder and its sectors of psychopathology. Arch Gen Psychiatry. 2011;68:753–762. doi: 10.1001/archgenpsychiatry.2011.65. - DOI - PMC - PubMed

MeSH terms

Substances